| MeSH term | MeSH ID | Detail |
|---|---|---|
| Anemia, Refractory | D000753 | 3 associated lipids |
| Wounds, Stab | D014951 | 3 associated lipids |
| Pityriasis | D010915 | 3 associated lipids |
| Uveitis, Intermediate | D015867 | 3 associated lipids |
| Legionellosis | D007876 | 3 associated lipids |
| Drug-Related Side Effects and Adverse Reactions | D064420 | 3 associated lipids |
| Glomerulonephritis, Membranoproliferative | D015432 | 3 associated lipids |
| Hepatolenticular Degeneration | D006527 | 3 associated lipids |
| Keratosis, Actinic | D055623 | 3 associated lipids |
| Failed Back Surgery Syndrome | D055111 | 3 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| McCune TR et al. | Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. | 1998 | Transplantation | pmid:9448150 |
| Mentzer RM et al. | Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group. | 1998 | Transplantation | pmid:9448154 |
| Burroughs TE et al. | Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. | 2007 | Transplantation | pmid:17452891 |
| First MR | Transplantation in the nineties. | 1992 | Transplantation | pmid:1370734 |
| Méndez A et al. | Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation. | 2014 | Transplantation | pmid:24492423 |
| Fridell JA et al. | Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. | 2006 | Transplantation | pmid:16906038 |
| Misra S et al. | Red cell aplasia in children on tacrolimus after liver transplantation. | 1998 | Transplantation | pmid:9500636 |
| Reutzel-Selke A et al. | Short-term immunosuppressive treatment of the donor ameliorates consequences of ischemia/ reperfusion injury and long-term graft function in renal allografts from older donors. | 2003 | Transplantation | pmid:12811235 |
| Hougardy JM et al. | The once-daily formulation of tacrolimus: a step forward in kidney transplantation? | 2012 | Transplantation | pmid:22234346 |
| Hoffman AL et al. | The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. | 1990 | Transplantation | pmid:1690469 |
| D'Antiga L et al. | Late cellular rejection in paediatric liver transplantation: aetiology and outcome. | 2002 | Transplantation | pmid:11792983 |
| Butani L et al. | Effect of felodipine on tacrolimus pharmacokinetics in a renal transplant recipient. | 2002 | Transplantation | pmid:11793001 |
| Velidedeoglu E et al. | Early kidney dysfunction post liver transplantation predicts late chronic kidney disease. | 2004 | Transplantation | pmid:15084934 |
| Leung W et al. | Long-term complete remission and immune tolerance after intensive chemotherapy for lymphoproliferative disorders complicating liver transplant. | 1999 | Transplantation | pmid:10385092 |
| Guo Z et al. | In vivo effects of leflunomide on normal pancreatic islet and syngeneic islet graft function. | 1997 | Transplantation | pmid:9075844 |
| Xu X et al. | FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506. | 2002 | Transplantation | pmid:12085010 |
| Mueller AR et al. | Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506. | 1994 | Transplantation | pmid:7518974 |
| Platz KP et al. | Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. | 1994 | Transplantation | pmid:7518975 |
| Takaya S et al. | Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. | 1992 | Transplantation | pmid:1279851 |
| Wasik M et al. | Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. | 1991 | Transplantation | pmid:1702910 |
| Carroll PB et al. | Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. | 1991 | Transplantation | pmid:1702911 |
| Sarwal MM et al. | Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. | 2001 | Transplantation | pmid:11468528 |
| Nobori S et al. | Long-term acceptance of fully allogeneic cardiac grafts by cotransplantation of vascularized thymus in miniature swine. | 2006 | Transplantation | pmid:16421473 |
| Yu S et al. | Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. | 2006 | Transplantation | pmid:16421475 |
| Macphee IA et al. | Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. | 2002 | Transplantation | pmid:12490779 |
| Luan FL et al. | New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. | 2011 | Transplantation | pmid:21242885 |
| Takatsuki M et al. | Weaning of immunosuppression in living donor liver transplant recipients. | 2001 | Transplantation | pmid:11502975 |
| Shapiro R et al. | Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. | 2008 | Transplantation | pmid:18431232 |
| Iwata H et al. | Suppression of allograft responses by combining donor alloantigen-specific intravenous presensitization with suboptimal doses of FK506. | 1993 | Transplantation | pmid:7687396 |
| Panz VR et al. | Diabetogenic effect of tacrolimus in South African patients undergoing kidney transplantation1. | 2002 | Transplantation | pmid:11889436 |
| Charney DA et al. | Plasma cell-rich acute renal allograft rejection. | 1999 | Transplantation | pmid:10515379 |
| Fisher NC et al. | The clinical impact of nephrotoxicity in liver transplantation. | 2000 | Transplantation | pmid:10910259 |
| Brunet M et al. | Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. | 2006 | Transplantation | pmid:16495801 |
| MacDonald AS | Management strategies for nephrotoxicity. | 2000 | Transplantation | pmid:10910262 |
| Kessler L et al. | Tacrolimus-associated optic neuropathy after pancreatic islet transplantation using a sirolimus/tacrolimus immunosuppressive regimen. | 2006 | Transplantation | pmid:16495816 |
| Moffatt SD and Metcalfe SM | Comparison between tacrolimus and cyclosporine as immunosuppressive agents compatible with tolerance induction by CD4/CD8 blockade. | 2000 | Transplantation | pmid:10836388 |
| Randhawa PS et al. | Clinical significance of renal biopsies showing concurrent acute rejection and tacrolimus-associated tubular vacuolization. | 1999 | Transplantation | pmid:9921801 |
| Higgins RM et al. | Conversion from tacrolimus to cyclosporine in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. | 2000 | Transplantation | pmid:10836393 |
| Meiser BM | The best dosing for initial tacrolimus application is trough level adapted! | 2005 | Transplantation | pmid:15714162 |
| Garton T | Nefazodone and cyp450 3a4 interactions with cyclosporine and tacrolimus1. | 2002 | Transplantation | pmid:12352898 |
| Hougardy JM et al. | Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. | 2011 | Transplantation | pmid:21192316 |
| Ochiai T et al. | Studies of the effects of FK506 on renal allografting in the beagle dog. | 1987 | Transplantation | pmid:2447688 |
| Miao G et al. | Development of donor-specific immunoregulatory T-cells after local CTLA4Ig gene transfer to pancreatic allograft. | 2004 | Transplantation | pmid:15257039 |
| Peng Y et al. | Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. | 2013 | Transplantation | pmid:23263506 |
| Chavin KD et al. | Anti-CD2 monoclonal antibodies synergize with FK506 but not with cyclosporine or rapamycin to induce tolerance. | 1994 | Transplantation | pmid:7511258 |
| Ricordi C et al. | In vivo effect of FK506 on human pancreatic islets. | 1991 | Transplantation | pmid:1716797 |
| Katz IA et al. | Comparison of the effects of FK506 and cyclosporine on bone mineral metabolism in the rat. A pilot study. | 1991 | Transplantation | pmid:1716801 |
| Wiesner RH | A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. | 1998 | Transplantation | pmid:9734494 |
| Chan L et al. | Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. | 2010 | Transplantation | pmid:20517177 |
| Hodak SP et al. | QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. | 1998 | Transplantation | pmid:9734501 |